Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Inclusion Criteria:

diagnosed with stage I-IV ovarian, peritoneal or fallopian tube cancer
completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being enrolled in the study (can be on bevacizumab maintenance)
in remission of their disease at the time of enrollment between 21 and 70 years of age
fluent in English
in the judgment of the consenting professional, have capacity to give consent

Healthy Control Inclusion Criteria:

no diagnosis of cancer except basal cell carcinoma
between 21 and 70 years of age
fluent in English
has a mini-mental state exam (MMSE) score of 26 or higher
in the judgment of the consenting professional, have capacity to give consent

Exclusion Criteria:

active or recurrent disease, or diagnosis of another cancer (except basal cell carcinoma) as per medical records at the time of enrollment
exposure to chemotherapy or radiation therapy for any medical condition unrelated to ovarian cancer
on hormonal therapy at the time of enrollment
neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.
self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia
unable to complete cognitive tests
with standard contraindications to MRI examinations

Healthy Control Exclusion Criteria:

exposure to chemotherapy or radiation therapy for any medical condition
on hormone replacement therapy at the time of enrollment
neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.